Last reviewed · How we verify
NCT03212027
Preoperative Prediction of of Thymic Epithelial Tumors by Diffusion-Weighted MR Imaging
trial in Thymic Epithelial Tumor in 60 participants. Status unknown.
1 January 2018
Quick facts
| Lead sponsor | Tang-Du Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 31 July 2017 |
| Primary completion | 1 January 2018 |
| Estimated completion | 1 May 2018 |
Conditions studied
- Thymic Epithelial Tumor — all drugs for Thymic Epithelial Tumor →
Sponsor
Tang-Du Hospital
Who can join
Eligibility, any sex, with Thymic Epithelial Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to analyze aquaporins expression of thymic epithelial tumors and to compare them with apparent diffusion coefficient(ADC) from ultra-high b-values, and to test a possibility of use of ADCuh to identify the pathological type of tumor.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03212027
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Thymic Epithelial Tumor
Currently open trials in the same condition.
- NCT06311955 — Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor · Phase 2 · recruiting
- NCT06692062 — Hypofractionated Radiotherapy for Thymic Epithelial Tumors · NA · recruiting
- NCT06301945 — Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors · recruiting
- NCT05104736 — PT-112 in Subjects With Thymoma and Thymic Carcinoma · Phase 2 · recruiting
- NCT04417660 — Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma · Phase 2 · active not recruiting
Other Tang-Du Hospital trials
Trials by the same sponsor.
- NCT07528235 — An Open-Label, Dose-Escalation Study on the Safety, Tolerability and Preliminary Efficacy for Preventing SAP by Intraven · Phase 1 · not yet recruiting
- NCT07516522 — Intra-arterial Methylprednisolone After Endovascular Thrombectomy · Phase 2 · recruiting
- NCT07354061 — Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC) · Phase 1, PHASE2 · recruiting
- NCT07327736 — Anesthesia Comparison in Early-stage Small NSCLC: A Multicenter RCT · NA · not yet recruiting
- NCT07452601 — Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03212027 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tang-Du Hospital
- Last refreshed: 18 July 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03212027.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing